Neoadjuvant pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer: a nationwide retrospective Turkish oncology group study

Basit Öğe Kaydı
dc.contributor.authorKarcı, Ebru
dc.contributor.authorBilici, Ahmet
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorSakin, Abdullah
dc.contributor.authorGünaldı, Meral
dc.contributor.authorEsin, Ece
dc.contributor.authorYıldız, Özcan
dc.date.accessioned2025-10-06T07:14:31Z
dc.date.available2025-10-06T07:14:31Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground/Objectives: Following the results of the phase 3 KEYNOTE-522 trial, the U.S. Food and Drug Administration approved pembrolizumab, a humanized IgG4 kappa monoclonal antibody, in combination with neoadjuvant chemotherapy as a new standard of care for high-risk early-stage triple-negative breast cancer (TNBC). This retrospective, multicenter study in Türkiye assessed the real-world efficacy and safety of neoadjuvant pembrolizumab combined with chemotherapy in early-stage TNBC. Methods: The study included 108 patients treated between 2021 and 2023 across 14 oncology centers. Three distinct neoadjuvant regimens incorporating pembrolizumab were administered at the discretion of the treating physicians. The primary outcomes were the pathological complete response (pCR) rate after neoadjuvant therapy and the 2-year event-free survival (EFS) and overall survival (OS) rates. Results: The observed pCR rate was 63.9%, closely mirroring the 64.8% reported in the KEYNOTE-522 trial. At the two-year mark, the EFS rate was 87.2% and the OS rate was 92.3%. Multivariable analysis identified pCR as the sole independent predictor of both EFS and OS. The safety profile was consistent with previous clinical trial data, with most adverse events being of grade 1–2 in severity. Conclusions: These findings provide valuable real-world confirmation of the efficacy and safety of neoadjuvant pembrolizumab–chemotherapy in early-stage TNBC, complementing evidence from randomized trials.
dc.identifier.citationKarcı, E., Bilici, A., Ölmez, Ö. F., Sakin, A., Günaldı, M., Esin, E. ... Yıldız, Ö. (2024). Neoadjuvant pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer: a nationwide retrospective Turkish oncology group study. Cancers, 16(19). http://dx.doi.org/10.3390/cancers16193389
dc.identifier.doi10.3390/cancers16193389
dc.identifier.issn2072-6694
dc.identifier.issue19
dc.identifier.pmid39410009
dc.identifier.scopus2-s2.0-85206571312
dc.identifier.scopusqualityQ1
dc.identifier.urihttp://dx.doi.org/10.3390/cancers16193389
dc.identifier.urihttps://hdl.handle.net/20.500.12511/13073
dc.identifier.volume16
dc.identifier.wosWOS:001331766600001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKarcı, Ebru
dc.institutionauthorBilici, Ahmet
dc.institutionauthorÖlmez, Ömer Fatih
dc.institutionauthorSakin, Abdullah
dc.institutionauthorYıldız, Özcan
dc.institutionauthorid0000-0001-8802-6376
dc.institutionauthorid0000-0002-0443-6966
dc.institutionauthorid0000-0002-0443-6966
dc.institutionauthorid0000-0003-2538-8569
dc.institutionauthorid0000-0003-2342-073X
dc.language.isoen
dc.relation.ispartofCancers
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectEvent-Free Survival
dc.subjectNeoadjuvant Therapy
dc.subjectOverall Survival
dc.subjectPathological Complete Response
dc.subjectPembrolizumab
dc.subjectReal World
dc.subjectSafety
dc.subjectTriple-Negative Breast Cancer
dc.titleNeoadjuvant pembrolizumab plus chemotherapy in early-stage triple-negative breast cancer: a nationwide retrospective Turkish oncology group study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Karcı-Ebru-2024.pdf
Boyut:
943.58 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu